Maureen F Zakowski

Summary

Publications

  1. doi The role of fine needle aspiration cytology in the diagnosis and management of thymic neoplasia
    Maureen F Zakowski
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 5:S281-5. 2010
  2. doi Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Sandra P D'Angelo
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:1815-22. 2012
  3. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
  4. pmc Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6169-77. 2012
  5. pmc Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Mol Cancer Ther 11:485-91. 2012
  6. doi Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center
    Sandra P D'Angelo
    Memorial Sloan Kettering Cancer Center, New York, NY 10019, USA
    J Thorac Cardiovasc Surg 141:476-80. 2011
  7. doi Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas
    Maria E Arcila
    Department of Pathology, and Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:4910-8. 2012
  8. doi Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
  9. pmc Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 6:569-75. 2011
  10. doi Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions
    Yoshiyuki Suehara
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6599-608. 2012

Collaborators

Detail Information

Publications23

  1. doi The role of fine needle aspiration cytology in the diagnosis and management of thymic neoplasia
    Maureen F Zakowski
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 5:S281-5. 2010
    ..We show that needle aspiration sampling of thymic tumors, both thymoma and thymic carcinoma, is an accurate method of diagnosis...
  2. doi Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
    Sandra P D'Angelo
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:1815-22. 2012
    ..The clinical significance of these mutations in patients with resected stage I-III lung cancers is unclear...
  3. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  4. pmc Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6169-77. 2012
    ..The molecular epidemiology of most EGFR and KRAS mutations in lung cancer remains unclear...
  5. pmc Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Mol Cancer Ther 11:485-91. 2012
    ..Given the high frequency of overlapping mutations, comprehensive genotyping should be carried out on tumor specimens from patients enrolling in clinical trials of PI3K and other targeted therapies...
  6. doi Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center
    Sandra P D'Angelo
    Memorial Sloan Kettering Cancer Center, New York, NY 10019, USA
    J Thorac Cardiovasc Surg 141:476-80. 2011
    ....
  7. doi Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas
    Maria E Arcila
    Department of Pathology, and Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:4910-8. 2012
    ..The prevalence, clinicopathologic characteristics, prognostic implications, and molecular heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients...
  8. doi Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
    ..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction...
  9. pmc Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 6:569-75. 2011
    ..Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown...
  10. doi Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions
    Yoshiyuki Suehara
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6599-608. 2012
    ..We conducted a systematic search for tyrosine kinase fusions by screening all tyrosine kinases for aberrantly high RNA expression levels of the 3' kinase domain (KD) exons relative to more 5' exons...
  11. pmc Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:511-22. 2013
    ..These findings have practical implications for diagnosis, predictive molecular testing and therapy selection...
  12. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
    ..Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish the frequency of various mechanisms has not been conducted...
  13. doi Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
    ..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice...
  14. pmc EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cancer Ther 12:220-9. 2013
    ..Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors...
  15. doi Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
    Adnan Hasanovic
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lung Cancer 77:299-305. 2012
    ..Specific antibodies that can detect mutant EGFR protein were evaluated for the detection of EGFR mutation by immunohistochemistry (IHC) in cytology and small biopsy specimens...
  16. doi Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas
    Katharine Lampen-Sachar
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lung Cancer 75:332-5. 2012
    ..To compare preoperative size of stage I and stage II lung adenocarcinoma as measured by Computed Tomography (CT) and as assessed on gross pathology specimens...
  17. pmc Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
    J Matthew Reinersman
    Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:28-31. 2011
    ..KRAS mutations confer resistance to EGFR-tyrosine kinase inhibitors. The prevalence of these mutations in African American patients has not been thoroughly investigated...
  18. pmc Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Maria E Arcila
    Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:1169-80. 2011
    ..Positive cases were evaluated for T790M using standard PCR-based methods and a subset were re-evaluated with an LNA-PCR/sequencing method with an analytical sensitivity of approximately 0.1%. MET amplification was assessed by FISH...
  19. doi Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies
    Mark L Kayton
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 5:1764-71. 2010
    ..Herein, we present clinical, histopathologic, and molecular data on eight such cases...
  20. doi Insulin-like growth factor-1 receptor expression in thymic malignancies
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
    J Thorac Oncol 5:1439-46. 2010
    ..As higher levels of IGF-1R protein expression may be associated with relative sensitivity to anti-IGF-1R antibody treatment, we investigated IGF-1R expression in thymic malignancies...
  21. doi Aspiration cytomorphology of fetal adenocarcinoma of the lung
    Kim R Geisinger
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Am J Clin Pathol 134:894-902. 2010
    ....
  22. doi The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
    Matthew Bott
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 43:668-72. 2011
    ..These findings implicate transcriptional deregulation in the pathogenesis of MPM...
  23. doi Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature
    Ruta Gupta
    Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Arch Pathol Lab Med 132:926-30. 2008
    ..Evidence-based pathology promotes the use of systematic reviews of literature and meta-analysis of data to synthesize the results of multiple publications...